Please ensure Javascript is enabled for purposes of website accessibility

Why Cassava Sciences Was Up 15% in May

By Jason Hawthorne - Jun 7, 2021 at 2:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Thanks to key funding, its Alzheimer's drug is on track even after Biogen's historic approval.

What happened

Shares of Cassava Sciences (SAVA 10.97%) rose 15% in May, according to data provided by S&P Global Market Intelligence. After a positive meeting with the Food and Drug Administration (FDA) in February, its treatment for Alzheimer's Disease (AD) got more good news in May: It received a $2.7 million grant from the National Institutes of Health (NIH).

So what

The relationship isn't new. The biotech has been developing the drug for more than 10 years and the NIH has been providing funding since 2017. 

A person helping an older person in a wheel chair put together a puzzle at a table outdoors.

Image source: Getty Images.

The money will help it move the drug into a pair of phase 3 trials later this year. The first will enroll 1,000 participants and study the drug's ability to slow the rate of decline in cognition and health function. The second cohort, of 600 participants, will be studied for dementia-related behavior.

Although all eyes will be on Biogen (BIIB -0.29%) after the FDA's historic approval of its Alzheimer's drug, aducanumab, the NIH funding keeps the momentum going for Cassava. In a phase 2 study, its own candidate, simufilam, demonstrated a 10% improvement in cognition versus baseline and a 29% improvement in dementia-related behavior.

Now what

The approval of aducanumab presents both an opportunity and a risk for Cassava. On one hand, Biogen's drug did not have particularly stellar results in clinical trials. It only showed efficacy in one of two phase 3 studies. In fact, an FDA advisory panel recommended against its approval in November. That means the bar for simufilam is low. On the other hand, many patients may naturally gravitate to Biogen's approved drug instead of enrolling in a clinical trial. If that happens, it could drag out the timeline -- and increase the costs -- of clinical trials.

So far, Wall Street is betting on the more positive outcome. Shares of Cassava have continued to rise, up 30% in June so far. With superior efficacy and no royalty obligations, shareholders willing to be patient should be rewarded if the drug's performance holds up. Although it may have a head start, Biogen's news might turn out to be even better for Cassava over the next few years.

Jason Hawthorne has no position in any of the stocks mentioned. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cassava Sciences, Inc. Stock Quote
Cassava Sciences, Inc.
$19.42 (10.97%) $1.92
Biogen Inc. Stock Quote
Biogen Inc.
$217.56 (-0.29%) $0.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.